| Literature DB >> 25858591 |
Patricio Lopez-Jaramillo, Diego Gomez-Arbelaez, Aristides Sotomayor-Rubio, Daniel Mantilla-Garcia, Jose Lopez-Lopez.
Abstract
The current epidemic of obesity and cardiometabolic diseases in developing countries is described as being driven by socioeconomic inequalities. These populations have a greater vulnerability to cardiometabolic diseases due to the discrepancy between the maternal undernutrition and its consequence, low-birth weight progeny, and the subsequent modern lifestyles which are associated with socioeconomic and environmental changes that modify dietary habits, discourage physical activity and encourage sedentary behaviors. Maternal undernutrition can generate epigenetic modifications, with potential long-term consequences. Throughout life, people are faced with the challenge of adapting to changes in their environment, such as excessive intake of high energy density foods and sedentary behavior. However, a mismatch between conditions experienced during fetal programming and current environmental conditions will make adaptation difficult for them, and will increase their susceptibility to obesity and cardiovascular diseases. It is important to conduct research in the Latin American context, in order to define the best strategies to prevent the epidemic of cardiometabolic diseases in the region.Entities:
Mesh:
Year: 2015 PMID: 25858591 PMCID: PMC4346113 DOI: 10.1186/s12916-015-0293-8
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Global trends in fasting plasma glucose and diabetes prevalence (1980 vs. 2008)
|
|
|
|
|---|---|---|
| Global FPG (mmol/L)* | ||
| Men | 5.29** | 5.50 (5.37–5.63) |
| Women | 5.15** | 5.42 (5.29–5.54) |
| DM2 prevalence (%)* | ||
| Men | 8.3 (6.5–10.4) | 9.8 (8.6–11.2) |
| Women | 7.5 (5.8–9.6) | 9.2 (8.0–10.5) |
| People with DM2 (million)* | ||
| Men | 77 (60–97) | 173 (151–197) |
| Women | 76 (58–97) | 173 (151–197) |
*Age-standardized values. **Estimated values from the published data [16]. Data is presented as mean (95% uncertainty interval). FPG: fasting plasma glucose. DM2: diabetes mellitus type 2.
Prevalence of metabolic syndrome in Latin American countries
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Chile | 2003 | 1833 | ≥17 | ATP-III | 32.0 |
| IDF | 37.0 | ||||
| Mexico | 2006 | 6021 | 20 to 69 | ATP-III | 36.8 |
| IDF | 49.8 | ||||
| Venezuela | 2001 | 3108 | ≥20 | ATP-III | 31.2 |
| Ecuador | 2004 | 352 | ≥65 | IDF | 40.0 |
| Peru | 2006 | 1878 | 20 to 80 | AHA/NHLBI | 18.8 |
| Brazil | 2001 | 1655 | 25 to 64 | ATP-III | 32.9 |
| Colombia | 2007 | 1001 | ≥18 | ATP-III | 45.6 |
| IDF | 50.4 |
Extracted values from published data [19,22-28]. MS: metabolic syndrome.
Global and Latin American rates of awareness, treatment and control of cardiovascular diseases – PURE study
|
|
|
|
|---|---|---|
| Hypertension | ||
| Awareness | 46.5 | 57.1 |
| Treatment | 40.6 | 52.8 |
| Control | 13.2 | 18.8 |
| Secondary preventive drugs | ||
| Antiplatelet drugs | 25.3 | 29.0 |
| β-blockers | 17.4 | 28.8 |
| ACE / ARB | 19.5 | 37.9 |
| Statins | 14.6 | 15.0 |
| Healthy lifestyle | ||
| Smoking cessation | 53.4 | 67.2 |
| Physical activity | 35.1 | 41.5* |
| Healthy diets | 39.0 | 43.2* |
Extracted values from published data [32-34]. *Data for the global lower-middle-income countries, where the Latin Americans are included. ACE: angiotensin-converting-enzyme inhibitors. ARB: angiotensin-receptor blockers.
Figure 1Epigenetic modifications and environmental influences on the pathogenesis of cardiometabolic diseases.